1. Generics Bulletin
  2. >>Business

Indoco Works To Unblock Barriers To Growth

 
• By Aidan Fry

India’s Indoco Remedies must address facility deficiencies highlighted by authorities in both the US and EU before it can revive its flagging formulations exports operation and restore top-line growth.

ManClipboard
Facility deficiencies highlighted by inspectors from both the US and the EU are thwarting Indoco's hopes of generating growth from highly regulated markets • Source: Shutterstock

Indoco Remedies is struggling to convince the US Food and Drug Administration (FDA) that its facilities in Goa, India, meets compliance standards. An FDA inspection of the firm’s Goa Plant I oral-dose plant concluded from 17-25 January resulted in six ‘Form 483’ observations.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Manufacturing

More from Business

Iconovo Slims Down As It Focuses On Commercialization

 
• By Dave Wallace

As its need for development resources declines, Iconovo is cutting staff to save money as it moves to the commercialization stage for its portfolio of off-patent inhaled products.

Roche Suggests Perjeta Biosimilars May Not Hit Until 2027 ‘Or Later’

 
• By Dean Rudge

Amid several insights into its expectations of biosimilar competition in 2025, Roche has confirmed the total amount it anticipates being shaved from its top line this year.

Hikma Doubles Down On 2025 Guidance Despite Tariff Anxiety And Injectables Competition

 
• By Adam Zamecnik

Despite industry-wide uncertainty surrounding the Trump administration’s interest in pharma-focused tariffs, Hikma has maintained its guidance for the 2025 financial year.